Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Heart Health Highlights: New data on semaglutide | Weight loss products recalled over possible heart damage, other risks
Monday, September 18, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Heart Health

Weight loss drug semaglutide linked to better heart health, but high costs may limit its impact

It could cost more than $1 million just to avoid a single heart attack, stroke or cardiovascular death, researchers wrote. 

READ MORE >
money maze payment reimbursement
Share on Twitter Share on Facebook Share on Linkedin

Weight loss drug semaglutide linked to better heart health, but high costs may limit its impact

Share on Twitter Share on Facebook Share on Linkedin
money maze payment reimbursement
It could cost more than $1 million just to avoid a single heart attack, stroke or cardiovascular death, researchers wrote. 
READ MORE >

First 10 drugs chosen by White House for Medicare price negotiations include blood thinners, heart failure meds

Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House. 

READ MORE >
Money dollar investments
Share on Twitter Share on Facebook Share on Linkedin

First 10 drugs chosen by White House for Medicare price negotiations include blood thinners, heart failure meds

Share on Twitter Share on Facebook Share on Linkedin
Money dollar investments
Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House. 
READ MORE >

Medtronic faces class-action lawsuit after patient data shared with Google, other third-party sites

The complaint describes Medtronic's actions as “immoral, unethical, oppressive and unscrupulous.”

READ MORE >
Medtronic faces lawsuit for sharing data of customers who used the InPen smartphone app
Share on Twitter Share on Facebook Share on Linkedin

Medtronic faces class-action lawsuit after patient data shared with Google, other third-party sites

Share on Twitter Share on Facebook Share on Linkedin
Medtronic faces lawsuit for sharing data of customers who used the InPen smartphone app
The complaint describes Medtronic's actions as “immoral, unethical, oppressive and unscrupulous.”
READ MORE >

Seeds for weight loss recalled: FDA says they are a ‘highly toxic’ plant containing cardiac glycosides

The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides.

READ MORE >
the words "FDA recall" on a board
Share on Twitter Share on Facebook Share on Linkedin

Seeds for weight loss recalled: FDA says they are a ‘highly toxic’ plant containing cardiac glycosides

Share on Twitter Share on Facebook Share on Linkedin
the words "FDA recall" on a board
The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides.
READ MORE >

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Share on Twitter Share on Facebook Share on Linkedin
Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 
READ MORE >

FDA clears new smart scale capable of detecting AFib, other cardiovascular issues

The Body Scan Connected Health Station includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle with four stainless steel electrodes.

READ MORE >
Withings Body Scan Connected Health Station FDA cleared
Share on Twitter Share on Facebook Share on Linkedin

FDA clears new smart scale capable of detecting AFib, other cardiovascular issues

Share on Twitter Share on Facebook Share on Linkedin
Withings Body Scan Connected Health Station FDA cleared
The Body Scan Connected Health Station includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle with four stainless steel electrodes.
READ MORE >

FDA panel votes in favor of Recor Medical renal denervation system

A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. 

READ MORE >
The U.S. Food and Drug Administration (FDA) has approved Recor Medical’s Paradise Ultrasound Renal Denervation (RDN) system for uncontrolled hypertension. The Recor system gained FDA clearance in November 2023.
Share on Twitter Share on Facebook Share on Linkedin

FDA panel votes in favor of Recor Medical renal denervation system

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) has approved Recor Medical’s Paradise Ultrasound Renal Denervation (RDN) system for uncontrolled hypertension. The Recor system gained FDA clearance in November 2023.
A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. 
READ MORE >

American College of Cardiology targets preventable heart disease with new screening campaign

The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.

READ MORE >
doctor with overweight patient who may be treated with TAVR or surgery
Share on Twitter Share on Facebook Share on Linkedin

American College of Cardiology targets preventable heart disease with new screening campaign

Share on Twitter Share on Facebook Share on Linkedin
doctor with overweight patient who may be treated with TAVR or surgery
The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.
READ MORE >

FDA panel votes not to endorse Medtronic renal denervation system

The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension.

READ MORE >
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.
Share on Twitter Share on Facebook Share on Linkedin

FDA panel votes not to endorse Medtronic renal denervation system

Share on Twitter Share on Facebook Share on Linkedin
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.
The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup